JULY 11, 2024 by Josh Baxt, UC Davis INBRX-101 is engineered to maximize the functional activity of AAT, particularly in the lung. Credit: UC DavisA multicenter safety study at UC Davis Health tested a protein drug (INBRX-101), developed to improve care for people with alpha-1 antitrypsin deficiency (AATD), and showed the therapy is quite safe....
